Sandoz H1 FY26 core diluted EPS rises 17% to USD 1.71; net sales climb 15% to USD 5.8 billion

Reuters2026/08/05 05:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sandoz posted H1 2026 net sales of USD 5.8 billion, up 15%.
Core-EBITDA margin widened 90 bps to 20.9%, while core diluted EPS climbed 17% to USD 1.71.
Management free cash flow was unchanged at USD 503 million.
Expanded the biosimilars pipeline to 36 assets; expected H2 2026 biosimilar launches include Enzeevu (aflibercept) and Ranluspec (ranibizumab).
Confirmed full-year 2026 guidance for mid-to high-single-digit net-sales growth and a core-EBITDA margin increase of about 100 bps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sandoz H1 FY26 core diluted EPS rises 17% to USD 1.71; net sales climb 15% to USD 5.8 billion

You may also like

Crypto prices